Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Inflammopharmacology ; 27(5): 1071-1080, 2019 Oct.
Article in English | MEDLINE | ID: mdl-30929154

ABSTRACT

Ischemic heart disease is a leading cause of death on a global scale, placing major socio-economic burdens on health systems worldwide. Myocardial ischaemia and reperfusion (I/R)-induced tissue injury is associated with alteration in activity of inflammatory system and nitric oxide pathway. Sumatriptan, which is mainly used to relieve migraine headache, has recently been shown to exert anti-inflammatory properties. In this study, we aimed to assess the possible cardioprotective effect of sumatriptan in a rat model of I/R injury. Male Wistar rats were subjected to 30-min ligation of left anterior descending coronary artery and 120-min reperfusion. Animals were randomly divided into five groups: (1) Sham (2) I/R (3) I/R treated with sumatriptan (0.3 mg/kg i.p.) 20 min after induction of I/R rats, (4) GR127935 (a selective antagonist of 5-HT1B/D serotonin receptors; 0.3 mg/kg) 20 min after induction of I/R, and (5) GR127935 (0.3 mg/kg) 15 min before administration of sumatriptan. Post-infarct treatment with sumatriptan increased left ventricular function, which was damaged in I/R animal's heart. Sumatriptan (0.3 mg/kg) decreased lipid peroxidation, CK-MB and lactate dehydrogenase levels; tumor necrosis factor concentration; and Nf-Ò¡B' protein production. Treatment with sumatriptan significantly increased the endothelial nitric oxide synthase (eNOS) expression consequences nitric oxide metabolites' level in I/R rats. Also, injection of sumatriptan remarkably decreased myocardial tissue injury assessed by histopathological study. These findings suggest that sumatriptan may attenuate I/R injury via modulating the inflammatory responses and endothelial NOS activity. But therapeutic index of sumatriptan is narrow according to the result of this study.


Subject(s)
Inflammation/drug therapy , Myocardial Reperfusion Injury/drug therapy , Protective Agents/pharmacology , Sumatriptan/pharmacology , Animals , Cardiotonic Agents/pharmacology , Inflammation/metabolism , Lipid Peroxidation/drug effects , Male , Myocardial Reperfusion Injury/metabolism , NF-kappa B/metabolism , Nitric Oxide/metabolism , Nitric Oxide Synthase Type III/metabolism , Rats , Rats, Wistar , Signal Transduction/drug effects , Ventricular Function, Left/drug effects
2.
Nanomedicine (Lond) ; 14(6): 675-687, 2019 Mar.
Article in English | MEDLINE | ID: mdl-30702017

ABSTRACT

AIM: To evaluate the antibiofilm effect and esp gene downregulation of Enterococcus faecalis through nanozinc oxide fabricated on natural zeolite (NanoZnO/Ze). Materials & methods:Zeolite and NanoZnO/Ze materials were characterized by x-ray diffraction, x-ray fluorescence and field emission scanning electron microscopy coupled with energy dispersive x-ray. Atomic absorption spectroscopy was used to evaluate zinc release. E. faecalis biofilm formation and its esp gene expression were assessed under nanocomposite treatment. RESULTS: Spherical-shaped ZnO nanoparticles with an average size of 30 nm were dispersed on the zeolites surface. The leakage of cationic zinc from NanoZnO/Ze displayed a long lasting and considerable release content (p < 0.0001) compared with ZnO/Ze. NanoZnO/Ze effectively inhibited (p < 0.0001) biofilm formation and affected esp gene downregulation of E. faecalis. CONCLUSION: Our results show that NanoZnO/Zeolite can potentiate against biofilm infections due to E. faecalis and possibly other pathogens.


Subject(s)
Anti-Infective Agents/chemistry , Biological Products/chemistry , Metal Nanoparticles/chemistry , Zeolites/chemistry , Zinc Oxide/chemistry , Biofilms , Delayed-Action Preparations/chemistry , Drug Liberation , Enterococcus faecalis/drug effects , Gene Expression Regulation/drug effects , Humans , Particle Size , Surface Properties , Zinc/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...